Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Mar 8, 2024
Discovery & Translation
Distillery spotlight: new ubiquitin-modulating mechanisms from academia
Innovators are finding new ways of targeting E3 ligases and DUBs in liver diseases and cancer: BioCentury’s survey of the 2023 translational literature
BioCentury | Feb 7, 2024
Deals
Tizona searching for new partner after Gilead declines buyout option
Gilead retains ownership of nearly half of Tizona’s equity via $300M investment in 2020, but won’t take full control of anti-HLA-G antibody
BioCentury | Apr 7, 2023
Emerging Company Profile
Geneos: DNA-based, personalized cancer vaccines
Inovio spin-out combining parent company’s plasmid delivery system with neoantigen technology from David Weiner’s lab at Wistar
BioCentury | Jun 2, 2022
Distillery Therapeutics
Bispecific antibodies targeting peptide–HLA complexes for HIV
BioCentury | Feb 9, 2022
Product Development
Tregs and gene regulation define Sangamo’s next act
Sangamo takes a second shot at a first mover advantage as it pivots from gene editing to engineering Treg cell therapies
BioCentury | Nov 29, 2021
Finance
U.S. crossovers help Quell raise $156M as Treg platform heads toward clinic
Series B syndicate for London biotech co-led by slate of U.S. and European investors
Items per page:
1 - 10 of 92